‘We took Ravgen head-on’: How we won zero-damages and others didn't

Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Natera stung for $57m in prenatal screening clash

18 January 2024 Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.

article

LabCorp hit with further $100m in DNA test patent case

16 May 2023 Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

‘We took Ravgen head-on’: How we won zero-damages and others didn't

More on this story

Editor's picks

Editor's picks

More features